US expansion Strategic acquisitions of FemiClear and Curoxen assets to bolster the women’s intimate health portfolio and establish a larger US footprint present a near-term opportunity to cross-sell and partner with US distributors, retailers, and e-commerce channels seeking complementary self-care brands.

UK direct access Direct access to the UK retail pharmacy and grocery channels with UltraDEX and Dentyl provides a proven pathway for regional upsell, bundling, and co-promotions with adjacent self-care portfolios in health and wellness for greater basket size.

Portfolio synergies Recent acquisitions and partnerships expand the women’s health and dermatology segments, creating opportunities to position cross-category bundles, private-label discussions, and exclusive formulations with retailers and manufacturers seeking integrated self-care solutions.

Manufacturing partnerships Long-term manufacturing agreement with BioDue and ongoing OEM/contract manufacturing capabilities suggest potential for white-labeling, toll manufacturing, and accelerated time-to-market for new self-care SKUs in international markets.

Growth financing Revenue scale is modest but growth ambitions via US market entry and brand portfolio expansion indicate a strong case for strategic partnerships, distribution deals, and investment-led collaborations with distributors, retailers, and healthcare-focused platforms looking to expand in the self-care space.